Researchers analyzed the unit prices of drugs classified as “high-spend” medications — based on volume, price or both — and found large price increases in this category.
Here are 10 “high-spend” drugs with the most significant price increases. The figures represent total spending by group purchasing organizations for more than 1,400 hospitals, according to the American Hospital Association.
Drug: 2013 spending — 2014 spending — 2015 spending
- Calcitonin-salmon: $4,932,748 — $12,529, 284 — $73,082,412
- Ephedrine sufate: $7,533,234 — $10,528,689 — $34,552,474
- Glycopyrrolate: $4,932,748 — $66,606,577 — $73,082,412
- Hydralazine: $6,951,150 — $7,725,372 — $17,568,936
- Isoproterenol: $5,602,447 —$23,066,826 — $86,541,461
- Neostigmine methysulfate: $56,818 — $4,311,153 — $78,814,217
- Nitroprusside: $9,802,140 —$48,278,606 — $94,966,434
- Phytonadione: $12,731,141 — $20,809,335 — $35,609,824
- Pyrimethamine: $595,748 — $801,690 — $812,109
- Sodium benzoate: $4,857,185 — $3,559,993 — $12,651,343
More articles on supply chain:
Roche subsidiary earns priority review status for drug Lucentis
St. Jude Medical issues warning on heart device after 2 patient deaths
Cost is king: 5 thoughts on the hospital supply chain from an expert who’s seen both sides of the business
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.